Future Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma

Pharmacy Times^® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62^nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

In this video, Trudel discusses closing thoughts on the results of the study and its implications for future treatment options for patients with RRMM.